Pfizer is committed to supporting people with hemophilia and to improving the long-term outcomes of their condition.
Evolution of Science and Innovation in Hemophilia: Pfizer’s Journey So Far
Pfizer continues to invest in the research and development of hemophilia treatment. View our Pfizer timeline of milestones in hemophilia, spanning from the early 1990s.
The projects mentioned above are for information only and may be available in India.
*Now known as Investigator Sponsored Research: https://www.pfizer.com/about/programs-policies/grants/investigator-sponsored-research [Accessed April 27, 2022].
†StatConsult is the legal manufacturer of Haemoassist® 2 and Pfizer holds sole distribution rights. Haemoassist® 2 is a CE-marked medical device in Europe, and is currently only available in Germany, Spain, Austria and Portugal, with more launches to come. Haemoassist® 2 is not intended for curing, treating, seeking treatment for, managing or diagnosing a specific disease or disorder, or any specific health condition. Pfizer will not have access to any personal information entered into Hemoassist® 2.
‡HemMobile® app is only available in certain markets. Restrictions may apply.
§HemMobile® Striiv™ Wearable is currently available in the United States and Argentina. HemMobile® is not intended for curing, treating, seeking treatment for, managing or diagnosing a specific disease or disorder, or any specific health condition.
ǁǁHEMOCRAFT™ is a trademark of Pfizer, Inc. Minecraft is a trademark of Mojang Synergies AB.
HEMOCRAFT™ is provided for educational purposes only and is not intended to replace discussions with a healthcare provider, nor is it intended for curing, treating, seeking treatment for, managing or diagnosing a specific disease or disorder or any specific health condition. HEMOCRAFT™ is currently available in the USA, Sweden and Italy.
¶Ultrasound imaging is not currently considered standard of care for the assessment of hemophilia in the
United Kingdom and other parts of the world. To find out whether you can access the Pfizer Ultrasound
Programme in your country, please speak to your local country Pfizer representative.
**My Hemophilia Centre app was part of a pilot programme in collaboration with The Royal London Hospital,
UK. The app is now being made more widely available in the United Kingdom, subject to local restrictions. My Hemophilia Centre app is provided for educational purposes only and is not intended for curing, treating, seeking treatment for, managing or diagnosing a specific disease or any specific health condition.
ASPIRE, Advancing Science and Patient care through Innovative Research and Education; ATDC, ataxia-telangiectasia group D-complementing; COVID-19, coronavirus disease 2019; FDA, Food and Drug Administration; HEAD-US, Hemophilia Early Arthropathy Detection with Ultrasound; HIV, human immunodeficiency virus; INSPIIRE, Integrated System for Pfizer Investigator-Initiated Research; NASA, National Aeronautics and Space Administration; SCID, severe combined immunodeficiency; WFH, World Federation of Hemophilia.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022